Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for REL/c-Rel Targeted Cancer Immunotherapy and Autoimmune Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for REL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | REL Recombinant Protein (Full-Length / Specific Domains) High purity (>95%), Endotoxin Controlled, Sequence Verified. HEK293 or E. coli expressed. |
View REL Products |
| Gene Delivery | REL Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and reporter assays. |
View REL Products |
| Benchmark Ab | Anti-REL Recombinant Antibody High-affinity positive control for Western Blot, ChIP, and IP assays. |
View REL Products |
| Validator | REL siRNA Set Sequence-verified knockdown pool for target validation. |
View REL Products |
| Related Target A | RELA (p65) Essential for counter-screening to ensure c-Rel selective inhibition. |
View RELA Products |
| Related Target B | NFKB1 (p50) Heterodimerization partner of c-Rel in B-cell signaling pathways. |
View NFKB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against other NF-kB family members (RELA, RELB) | High-purity recombinant REL, RELA, and RELB protein panels strictly verified by Mass Spectrometry. |
| High-throughput cellular reporter assay development | High-titer, sequence-verified Lentivirus for stable reporter cell line construction (NF-kB/c-Rel responsive elements). |
| Lack of reliable positive controls for binding assays | Recombinant Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive control antibodies included. |
| Off-target screening and phenotypic validation | Validated siRNA sets included for target-specific knockdown verification. |
Live REL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for REL (specifically c-Rel) therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum NF-kB inhibitors to highly selective c-Rel small molecules, PROTACs, and RNA therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the selective modulation of regulatory T cells (Tregs) and B-cell malignancies without triggering the systemic toxicity historically associated with general NF-kB inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | B-cell Lymphomas, Autoimmune Diseases | Selectivity Assay (Need Mutant vs WT Proteins, and homologous family panels like RELA) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Hematological Malignancies | Ubiquitination & Ternary Complex Assay (Need High-Purity Full-Length REL Protein) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Solid Tumors (Treg modulation) | In vitro knockdown verification (Need Sequence-Verified siRNA and Lentiviral Overexpression) |